Changements posologiques engendrés par le monitorage de la cyclosporine deux heures après la prise chez les patients greffés cardiaques

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Results of a Three-Year Prospective Study of C2 Monitoring in Long-Term Renal Transplant Recipients Receiving Cyclosporine Microemulsion

  2005cited by this paper
• Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus.

  2005cited by this paper
• Optimizing the immunosuppressive regimen in heart transplantation.

  2004cited by this paper
• Conversion to C2 monitoring of cyclosporine A exposure in maintenance kidney transplant recipients: results at 3 years.

  2004cited by this paper
• Therapeutic drug monitoring of cyclosporine.

  2004cited by this paper
• Chronic renal failure after transplantation of a nonrenal organ.

  2003cited by this paper
• Clinical validation studies of neoral C2 monitoring: a review

  2002cited by this paper
• Patient management by Neoral C2 monitoring: An international consensus statement1

  2002cited by this paper
• Recommendations for the Implementation of Neoral C2 Monitoring in Clinical Practice

  2002cited by this paper
• The evolution of therapeutic drug monitoring of cyclosporine.

  2001cited by this paper
• C2 single-point sampling to evaluate cyclosporine exposure in long-term renal transplant recipients.

  2001cited by this paper
• The temporal profile of calcineurin inhibition by cyclosporine in vivo.

  1999cited by this paper
• Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy.

  1998cited by this paper
• Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients.

  1998cited by this paper
• Comparison of neoral dose monitoring with cyclosporine through levels versus 2-hr postdose levels in stable liver transplant patients.

  1998cited by this paper
• Use of cyclosporine microemulsion (Neoral) in de novo and stable renal transplantation: clinical impact, pharmacokinetic consequences and economic benefits. Canadian and International Neoral Study Groups.

  1996cited by this paper
• Use of cyclosporine microemulsion (Neoral) in de novo and stable renal transplantation: clinical impact, pharmacokinetic consequences and economic benefits. Canadian and International Neoral Study Groups.

  1996cited by this paper
• Conversion and pharmacokinetic studies of a microemulsion formulation of cyclosporine in pediatric liver transplant patients.

  1996cited by this paper
• Use of cyclosporine microemulsion (Neoral) in De Novo and stable renal transplantation : Clinical impact, Pharmacokinetic consequences and economic benefits

  1996cited by this paper
• Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy.

  1988cited by this paper
• Cyclosporin-A--present experimental status.

  1981cited by this paper
• Cyclosporin-A--present experimental status.

  1981cited by this paper

• No citing papers are available for this paper.